TC
KNSA icon

TwinBeech Capital’s Kiniksa Pharmaceuticals KNSA Stock Holding History

TwinBeech Capital’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,595
Closed -$318K – 538
2026
Q1 		$318K Sell
6,595
-4,233
-39% -$188K 0.03% 441
2025
Q4 		$447K Buy
+10,828
New +$434K 0.03% 419

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

TwinBeech Capital's KNSA Position: Q2 2026 in Review

TwinBeech Capital sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2026, closing a stake of 6,595 shares — an estimated $318K sold.

TwinBeech Capital first reported a position in KNSA in Q4 2025 and held it in 2 quarters. The position peaked at $447K in Q4 2025. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • TwinBeech Capital reported no remaining Kiniksa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • TwinBeech Capital sold 6,595 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $318K.
  • TwinBeech Capital first reported a position in Kiniksa Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • TwinBeech Capital's Kiniksa Pharmaceuticals position peaked at $447K in Q4 2025.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on TwinBeech Capital's 13F filing for Q2 2026, filed 14 Aug 2026.